Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis

Background: Observational studies on the prognostic role of thyroid transcription factor 1 (TTF-1) in non-small cell lung cancer (NSCLC) are controversial. Methods: To clarify the impact of TTF-1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios and their corresponding 95% confidence intervals were calculated in terms of overall survival. Results: A total of 17 studies with 2,235 patients were evaluable for this meta-analysis. The studies were categorized by histology, disease stage and patient race. Our results suggested that TTF-1 overexpression had a favorable impact on survival of patients with NSCLC, the HR (95% CI) was 0.49 (0.42 to 0.55) overall, 0.46 (0.38-0.54) in Asian patients, 0.52 (0.42-0.63) in non-Asian patients, 0.45 (0.38-0.52) in adenocarcinoma, 0.63 (0.39-0.86) in stage I NSCLC, 0.43 (0.33-0.53) in stage IIIb-IV NSCLC. The data collected were not sufficient to determine the prognostic value of VEGF in patients with squamous cell lung carcinomas. But there was a high heterogeneity between the studies. Conclusions: TTF-1 overexpression indicates a favorable prognosis for patients with NSCLC, this effect appears also significant when the analysis is restricted in lung AC patients, stage I and stage IIIb-IV NSCLC.

[1]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[2]  F. Pezzella,et al.  Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. , 2012, Journal of thoracic disease.

[3]  J. Verdebout,et al.  The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2002, British Journal of Cancer.

[4]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[5]  J. Lafitte,et al.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Y. Yatabe,et al.  TTF-1 Expression in Pulmonary Adenocarcinomas , 2002, The American journal of surgical pathology.

[7]  Y. Ishikawa,et al.  Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. , 2010, Lung cancer.

[8]  J. Lafitte,et al.  Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[9]  Yong Song,et al.  Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Anthony J Alberg,et al.  Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[11]  R. Osarogiagbon.  Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. , 2012, Journal of thoracic disease.

[12]  Yan-wen Yao,et al.  Prognostic value of the ratio of ground glass opacity on computed tomography in small lung adenocarcinoma: A meta-analysis. , 2012, Journal of thoracic disease.

[13]  H. Nakamura,et al.  Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis , 2005, Thorax.

[14]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[15]  F. Puglisi,et al.  Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[16]  Yih-Leong Chang,et al.  Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. , 2012, Chest.

[17]  M Paesmans,et al.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.

[18]  G. Bepler,et al.  Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Kenji Suzuki,et al.  Bronchioloalveolar Carcinoma (Lepidic Growth) Component Is a More Useful Prognostic Factor than Lymph Node Metastasis , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  J. Verdebout,et al.  The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature , 2003, British Journal of Cancer.

[21]  I. Wistuba,et al.  Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome , 2012, Cancer.

[22]  F. Puglisi,et al.  Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. , 1997, Journal of clinical pathology.

[23]  J. Whitsett,et al.  Upstream Enhancer Activity in the Human Surfactant Protein B Gene Is Mediated by Thyroid Transcription Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[24]  C. Begg,et al.  Publication bias : a problem in interpreting medical data , 1988 .

[25]  M. Mattéi,et al.  Thyroid nuclear factor 1 (TTF‐1) contains a homeodomain and displays a novel DNA binding specificity. , 1990, The EMBO journal.

[26]  S. Wiseman,et al.  Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. , 2003, Human pathology.

[27]  B. Stripp,et al.  Regulation of Clara cell secretory protein gene transcription by thyroid transcription factor-1. , 1997, Biochimica et biophysica acta.

[28]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[29]  G. Pelosi,et al.  Immunoreactivity for Thyroid Transcription Factor-1 in Stage I Non–Small Cell Carcinomas of the Lung , 2001, The American journal of surgical pathology.

[30]  J. Silverman,et al.  Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. , 2004, Human pathology.

[31]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[32]  Alex J. Sutton,et al.  Contour-Enhanced Funnel Plots for Meta-Analysis , 2008 .

[33]  N. Ordóñez,et al.  Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. , 2000, The American journal of surgical pathology.

[34]  S. E. Kelly,et al.  Transcription of the Lung-specific Surfactant Protein C Gene Is Mediated by Thyroid Transcription Factor 1 (*) , 1996, The Journal of Biological Chemistry.

[35]  K. Kerr,et al.  Thyroid transcription factor 1 in pulmonary adenocarcinoma , 2004, Journal of Clinical Pathology.

[36]  V. Capelozzi,et al.  Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. , 2009, Lung cancer.

[37]  A. Borczuk,et al.  Expression of syndecan‐1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma , 2004, Cancer.

[38]  Liyan Wan,et al.  Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  P. Adegboyega,et al.  Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. , 2002 .

[40]  N. Myong.  Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins. , 2003, Journal of Korean medical science.

[41]  Dietel,et al.  Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B , 2000, Histopathology.

[42]  J. Ahn,et al.  Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  Q. Wang,et al.  The Role of Matrix Metalloproteinase 2 on the Survival of Patients with Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis , 2010, Cancer investigation.

[44]  Sheppard.  Specific markers for pulmonary tumours , 2000, Histopathology.

[45]  B. Chetaille,et al.  Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung , 2005, British Journal of Cancer.

[46]  P. Zhan,et al.  Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. , 2013, Journal of thoracic disease.

[47]  P. Zhan,et al.  The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis , 2012, Molecular Biology Reports.

[48]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[49]  J. Whitsett,et al.  Lung Cell-specific Expression of the Murine Surfactant Protein A (SP-A) Gene Is Mediated by Interactions between the SP-A Promoter and Thyroid Transcription Factor-1 (*) , 1995, The Journal of Biological Chemistry.

[50]  Lei Wang,et al.  The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. , 2008, Lung cancer.

[51]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[52]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.